OTC Bulletin Board

S & P Company Insight for CNS RESPONSE, INC.
 
 Profile

 
Business Summary: CNS Response, Inc., a life sciences company, focuses on the commercialization of a patented system that guides psychiatrists and other physicians in determining medications for patients with behavioral (mental or addictive) disorders.
 
Address
  2755 Bristol St., Suite 285
  Costa Mesa , CA 92626
  Phone: 714-545-3288
  Fax: 866-294-2611
  Website: http://www.cnsresponse.com
Auditor
  Cacciamatta Accountancy Corporation
  Irvine
Transfer Agent
  American Stock Transfer & Trust Co.
Employees:  21
ShareHolders:  354
Founded:  1984
Domicile:  Delaware
 
  
 
 Background

 
CNS Response, Inc., a life sciences company, focuses on the commercialization of a patented system that guides psychiatrists and other physicians in determining medications for patients with behavioral (mental or addictive) disorders. The company's technology, Referenced-EEG (rEEG) provides medical professionals with medication sensitivity data for a subject patient based upon the identification and correlation of treatment outcome information from other patients with similar neurophysiologic characteristics, which are contained in a proprietary outcomes database. It also offers laboratory information services, including rEEG reports based on quantitative EEG data supplied by the physician or an independent testing service. The company was founded in 2000 and is based in Costa Mesa, California.
History:  INCORPORATED in Delaware Mar. 20, 1987, as Age Research, Inc.; and on Apr. 30, 1987, merged its parent, Volt Research, Inc., a Utah corporation. Name changed to SalesTactix, Inc. Aug. 2, 2004, to Strativation, Inc. Sept. 7, 2005, and to CNS Response, Inc. Mar. 7, 2007 (through the merger of a wholly owned subsidiary of that name, which was organized in Delaware on Jan. 19, 2007). Volt Research was incorporated in Utah July 10, 1984, as Mammon Oil & Gas, Inc.; name changed to Volt Research, Inc. Feb. 26, 1986. March 7, 2007, acquired CNS Response, Inc., a California corporation organized on Jan. 11, 2000 (CNS California), through the merger of a wholly owned subsidiary of the company into CNS California. In the merger, the issued and outstanding Common shares of CNS California were converted into an aggregate of 9,845,132 Common shares of the company, and the issued and outstanding shares of Series A and B Preferred stock of CNS California were converted into 5,993,515 and 1,905,978 Common shares of the company, respectively.
 
Subsidiaries:
CNS Response, Inc. (California)
Colorado CNS Response, Inc.
Neuro-Therapy Clinic, P.C.
 
 
 
 
  
 
 Management

 

Management
OfficersPosition
 Leonard J. BrandtChairman, Secretary, Chief Financial Officer, Chief Executive Officer & Chief Accounting Officer
 George C. Carpenter, IVPresident
 Marty  TullioInvestor Relations Contact

Directors
 Leonard J. Brandt
 Henry T. Harbin
 David B. Jones
 Jerome  Vaccaro
 
  
 
 Annual Report

 
Annual Report
 
Income Statement
  20082007
REVENUES
Laboratory Information Services178,500238,400
Clinical Services595,000-
Total Revenues773,500238,400
EXPENSES
Cost of Laboratory Service Revenues(163,200)(166,200)
Sales and Marketing(881,400)(123,600)
General and Administrative(3,105,700)(1,775,600)
Research and Development(2,097,300)(1,442,600)
Interest Income, Net104,000(115,600)
Others-106,900
Earnings before Taxes(5,370,100)(3,278,300)
TAXES AND OTHER EXPENSES
Provision for Income Tax(1,400)(800)
Net Income (Loss)(5,371,500)(3,279,100)
SUPPLEMENTARY INFO
Operating Income (Loss)(5,474,100.00)(3,269,600.00)
Basic Eps-continuing Operations(0.21)(0.17)
Diluted Eps-continuing Operations(0.21)(0.17)
 
Balance Sheet
  20082007
Assets-
CURRENT ASSETS
Cash1,997,0005,790,100
Accounts Receivables98,20059,200
Prepaids and other189,400159,000
Total Current Assets2,284,6006,008,300
NON CURRENT ASSETS
Goodwill320,200-
Other Assets28,7004,100
Total Assets2,633,5006,012,400
Liabilities-
CURRENT LIABILITIES
Accounts Payable335,700219,400
Accrued Patient Costs397,500-
Deferred Compensation264,90073,400
Accrued Liabilities207,500207,500
Accrued Interest42,60035,800
Accrued Consulting Fees67,60073,200
Convertible Promissory Notes50,00050,000
Current Portion of Long-term Debt88,500-
Total Current Liabilities1,454,300659,300
NON CURRENT LIABILITIES
Notes Payable to officer118,600-
Capital Leases7,700-
SHAREHOLDERS' EQUITY
Common Stock-par Value25,30025,300
Additional Paid in Capital17,701,30016,630,000
Accumulated Deficit(16,673,700)(11,302,200)
Total Shareholders Equity1,052,9005,353,100
Total Liabilities & Shareholders Equity2,633,5006,012,400
 
  
 
 Interim Report

 
Interim Report   
 
Data Not Available
 
 
 
 
  
 
 Pro Forma Report

 
Pro Forma Report   
 
Data Not Available
 
 
 
 
  
 
 Quarterly Report

 
Quarterly Report Information   
 
Quarterly Revenue, US$
YearQuarterRevenue
  2009   1170,000
  2008   160,000
  2008   2220,000
  2008   3230,000
  2008   4260,000
  2008   Full Year 770,000
  2007   369,800,000
  2007   Full Year 240,000
 
 
Quarterly Net Income, US$
YearQuarterRevenue
  2009   1(1,430,000)
  2008   1(1,010,000)
  2008   2(1,310,000)
  2008   3(1,600,000)
  2008   4(1,450,000)
  2008   Full Year (5,370,000)
  2007   3(500,000)
  2007   Full Year (3,280,000)
  2006   Full Year 80,000
 
 
Quarterly EPS, US$
YearQuarterRevenue
  2009   1(.06)
  2008   1(.04)
  2008   2(.05)
  2008   3(.06)
  2008   4(.06)
  2008   Full Year (.21)
  2007   3(.02)
  2007   Full Year (.17)
 
  
 
 Stock Data

 
 
Capitalization as of 09/30/2008:
 
 Authorized SharesOutstanding Shares
Common $0.001 par750,000,00025,299,547
 
LONG TERM DEBT: $126,300.
 
Common $0.001 par
 
Stockholders:  01/06/2008, 354.
PRINCIPAL STOCKHOLDERS: May 17, 2007, Leonard Brandt owned or controlled 29.7% of the Common, David B. Jones 16.4% and Heartland Value Fund 9.1%.
 
Transfer Agent:  American Stock Transfer & Trust Co.   New York , NY
 
OTC Bulletin Board( Primary): CNSO
 
ExchangeYearHighLow
OTC Bulletin Board20083.00000.5100
OTC Bulletin Board20074.50000.7000
OTC Bulletin Board20068.50001.5000
OTC Bulletin Board20055.00001.5000
 
DIVIDENDS: Common $0.001 par: No cash. Common reverse split 1-for-50, Jan. 10, 2007.